Effects of dipeptidyl peptidase-4 (DPP-4) inhibitor, alogliptin, on coronary atherosclerosis in patients with type 2 diabetes mellitus
- Conditions
- Patients with type 2 diabetes mellitus who were suspected as having ischemic heart disease
- Registration Number
- JPRN-UMIN000015381
- Lead Sponsor
- Kanagawa PTCA Conference
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Not provided
(1)Patients who are suspected as having significant stenosis evaluated by CCTA and require to receive percutaneous coronary intervention (PCI) (2)Patients with acute coronary syndrome within 30 days (3)Patients with the past history of PCI(4)Patients with post coronary artery bypass grafting (CABG) (5)Patients with complex congenital heart disease (6)Patients with body mass index >35kg/m2 (7)Patients with the past history of heart failure (8)Patients with the past history of ketoacidosis or diabetic coma (9)Patients with hepatic disorder or with AST (GOT) or ALT (GPT) greater than 2 times of the upper limits of normal (10)Patients with renal dysfunction (estimated glomerular filtration rate 30 ml/min/1.73m2 or lower) (11)Patients with severe infection, pre or post operation, or severe trauma (12)Patients with a history of hypersensitivity to any of the components of alogliptin (13)Pregnant women, women suspected of being pregnant, or lactating women (14)Patients ineligible for the study determined by physicians
Study & Design
- Study Type
- Interventional,observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of FFR evaluated by CCTA (FFRCT)
- Secondary Outcome Measures
Name Time Method Change in plaque volume evaluated by CCTA Change in CT values evaluated by CCTA